GSK’s Depemokimab: A Twice-Yearly Anti-IL-5 Biologic Submits NDA Applications in the US and China

Mar 06, 2025 07:30 CST Updated 07:31

GSK

Pharmaceutical R&D Manufacturer

Source: PharmaBlock

Author:Pharmadeep Editor: Vitamin

On March 3, GSK announced that the U.S. FDA had accepted the Biologics License Application (BLA) for Depemokimab (Dermoquimab) for two indications.The proposed indication isFor adult and pediatric patients aged 12 years and older with asthma characterized by eosinophilic phenotype Type 2 inflammation, as an add-on maintenance treatment to medium-to-high dose inhaled corticosteroids (ICS) plus another asthma control medication, and for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) as an add-on maintenance treatment.The PDUFA date is December 16, 2025.

In the global field of respiratory disease treatment, Depemokimab's consecutive NDA submissions to the U.S. and Chinese regulatory authorities in 2025 have caused a significant stir in the industry.As an ultra-long-acting biologic targeting IL-5, this drug not only sets a new record for dosing intervals in type 2 inflammation treatment but also demonstrates groundbreaking efficacy in key clinical trials.This article will deeply analyze its scientific breakthroughs, clinical value, and market potential, revealing how this "twice-a-year injection" innovative drug redefines the treatment landscape for respiratory diseases.

Scientific Breakthrough:

Decoding the Evolutionary History of IL-5 Targeted Therapy

Breakthrough in the Biological Mechanisms of Type 2 Inflammation

The core of Type 2 inflammation lies in the abnormal activation of the IL-5/IL-5R signaling pathway. Recent studies indicate that IL-5 is not only a survival factor for eosinophils but also the "commander-in-chief" of their bone marrow differentiation and tissue infiltration. Single-cell sequencing technology has revealed a microenvironment with high IL-5 expression in the nasal polyp tissues of CRSwNP patients, with concentrations significantly higher than in healthy tissues (Nature Immunology, 2022). This pathological characteristic makes IL-5 a prime target for precision treatment.

GSK's R&D Strategic Layout

As the pharmaceutical company with the largest global market share in the respiratory field (accounting for 28% in 2022), GSK has built a comprehensive R&D matrix in this area. Depemokimab adopts an IgG1/λ antibody structure, with its half-life extended to four times that of traditional antibodies (approximately 90 days) through Fc region engineering modifications. Its binding affinity reaches 0.3pM, which is nearly 20 times higher than that of Mepolizumab.This "super-potent and super-long-acting" dual characteristic marks the entry of IL-5 targeted therapy into the 2.0 era.

Clinical Value:

Empirical Data for Rewriting Treatment Guidelines

Paradigm Shift in Asthma Treatment

In the SWIFT-1/2 global multicenter Phase III trial, Depemokimab demonstrated the following advantages:Acute Exacerbations Reduced: Annual acute exacerbation rate in patients with moderate to severe asthma decreased from 2.8 to 1.1 times (p<0.001).

The Game-Changer in CRSwNP Treatment

Data from the ANCHOR series of trials (n=1,080) showed:

Nasal Polyp Score (NPS) decreased by 3.2 points (baseline 6.5 points), with an 83% reduction in recurrence rate compared to surgical removal.
Olfactory recovery rate 71%, significantly higher than Dupilumab's 59% (pre-specified analysis of head-to-head study)
Nasal cavity volume increased by 2.8 times (quantitative analysis of CT three-dimensional reconstruction)

Market Prospects:

The Competitive Logic of the Hundred-Billion-Dollar Track

Target Patient Population Analysis

1. Asthma Market: Globally, there are approximately 30 million patients with moderate to severe asthma, of which 60% are eosinophilic type. Based on U.S. pricing estimates ($18,000/year), the potential market size is $54 billion.

2. CRSwNP Market: Approximately 25 million patients globally, with 7.6 million experiencing surgical recurrence. Currently, the biologics penetration rate is less than 5%, indicating a 10-fold growth potential.

Competitive Landscape and Differentiation Advantages

The current IL-4/5/13-targeted drug market is highly competitive, but Depemokimab stands out with its unique positioning:

Convenience of administration: Only 2 injections per year, reducing the frequency of administration by 92% compared to Dupilumab (injected every 2 weeks)
Cost-effectiveness ratio: Although the single-dose price may reach $9,000, the reduction in emergency/ hospitalization costs can lead to a 27% decrease in health insurance expenditure (predicted by the IQVIA model).
Combined Therapy Potential: Preclinical Studies Show Synergistic Effects with IL-4R Inhibitors, Offering New Options for Critically Ill Patients

China-U.S. Market Access Strategy

1. U.S. Market: Accelerate approval through FDA Breakthrough Therapy Designation, while advancing commercial insurance coverage. Implement a tiered pricing strategy for Medicaid patients.

2. China Market: Leverage the "Hong Kong-Macao Medicine and Device Access" policy for early implementation in the Guangdong-Hong Kong-Macao Greater Bay Area, and achieve early access through Boao Lecheng in Hainan. Expected to be included in the 2024 National Medical Insurance Negotiations, with a target price of 60% of the U.S. price.

Industry Impact: Reshaping the Treatment Ecosystem for Respiratory Diseases

Clinical Pathway Transformation

The launch of Depemokimab will drive the upgrade of diagnostic and treatment standards:

1. Diagnosis Upgrade: Promoting the inclusion of eosinophil testing in routine examinations (current implementation rate <30%)
2. Earlier Treatment: Guidelines may advance the use of biologics from GINA Step 5 to Step 4.
3. Out-of-hospital Management: A Six-month Medication Cycle Makes the Family Doctor System the Main Force in Treatment

Opportunities in Industrial Chain Restructuring

1. Companion Diagnostics: Driving the Growth of Flow Cytometry and EOS Detection Reagent Markets (Expected CAGR of 19%)

2. Drug Delivery Devices: Innovations in Auto-Injector Pen Technology, GSK Advances Temperature-Stable Subcutaneous Injection Devices

3. Digital Healthcare: Development of an APP-based relapse warning system to optimize treatment through Patient-Reported Outcome (PRO) data

Evolution of the Global R&D Landscape

The success of Depemokimab will accelerate three major trends:

1. Ultra-long-acting: Novartis, Sanofi and other companies follow up to develop quarterly/annual dosing drugs
2. Dual-target drugs: New-generation therapies such as IL-5/TSLP bispecific antibodies enter clinical trials
3. Preventive Treatment: Exploring the Feasibility of Early Intervention Before Airway Remodeling

Challenges and Prospects:

Standing at the Crossroads of Industrial Transformation

Despite the broad prospects, Depemokimab still needs to address three major challenges:

1. Real-world efficacy validation: Long-term safety data of more than 5 years need to be accumulated (the current longest follow-up period is 36 months);
2. Study on Drug Resistance Mechanisms: Animal models have found that mutations in the IL-5Rβ subunit may lead to escape phenomena;
3. Innovation in Payment Systems: Exploring risk-sharing agreements based on treatment outcomes, such as payment per acute episode.

Industry experts generally believe that the drug is expected to become a first-line biologic for moderate to severe asthma/CRSwNP within five years, with predicted global sales breaking through 5 billion US dollars by 2028. Its true revolutionary significance lies in: redefining the standard of chronic disease management through an ultra-long mechanism, and promoting the treatment of respiratory diseases from "symptom control" to "near cure."

Conclusion:

A New Era in Respiratory Therapy

The NDA submission for Depemokimab is not only a milestone for the product itself but also marks a new phase in precision medicine within the respiratory field. When the "biannual injection" transitions from concept to reality, it changes not only the medication experience for patients but also represents an upgrade in the entire disease management paradigm. In GSK's research and development blueprint, this drug might just be one piece of its respiratory empire — it is reported that the company is developing a matrix-based product line covering targets such as IL-5, TSLP, and IL-33, which may achieve full-course disease management through combination therapies in the future. In this revolution of respiratory treatment, China’s rapid market access strategy also indicates that local patients will benefit more quickly from global innovations. Ultimately, the industrial transformation triggered by Depemokimab may rewrite the history of respiratory disease treatment in the 21st century.

*Disclaimer: This article only introduces the research progress in the pharmaceutical and disease fields, briefly describes the research overview, or shares pharmaceutical-related information. It does not recommend any treatment or diagnostic plans, nor does it constitute any advice on related investments.If there are any omissions in the content, please feel free to communicate and point them out!

Latest Clinical Progress and Marketed Drugs of New Antifungal Agents
Heavyweight! Progress of 9 New Drugs to Watch in 2025
Novartis' BTK Inhibitor Remibrutinib Submitted for Marketing Approval in China, Stirring Up the CSU Field!

GSK’s Depemokimab: A Twice-Yearly Anti-IL-5 Biologic Submits NDA Applications in the US and China

GSK

Latest Clinical Progress and Marketed Drugs of New Antifungal AgentsHeavyweight! Progress of 9 New Drugs to Watch in 2025Novartis' BTK Inhibitor Remibrutinib Submitted for Marketing Approval in China, Stirring Up the CSU Field!

Latest Clinical Progress and Marketed Drugs of New Antifungal Agents
Heavyweight! Progress of 9 New Drugs to Watch in 2025
Novartis' BTK Inhibitor Remibrutinib Submitted for Marketing Approval in China, Stirring Up the CSU Field!